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benefit was measured preoperatively with only a hearing aid 
and postoperatively at EAS fitting and then 3, 6 and 12 
months after EAS fitting using the APHAB.  Results: Subjects 
reported significant improvements in the global score with 
a mean decrease in impairment from 74% preoperatively to 
45% after 3 months of EAS use. Furthermore, clinical rele-
vance was demonstrated in multiple subscales between pre-
operative and first fitting reflecting a true benefit of EAS 
with a probability of 95%.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 The combination of electric and acoustic hearing in 
the same ear, also known as electric-acoustic stimulation 
(EAS  ), is a relatively new treatment method for indi-
viduals with a ski slope type hearing loss mainly affecting 
the high frequencies who gain minimal or no benefit 
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 Abstract 
 Conclusion: This study demonstrates that electric-acoustic 
stimulation (EAS) significantly decreases the subjective im-
pairment in speech perception.  Objectives: To assess the 
subjective benefit of EAS over the first 12 months after EAS 
fitting using the Abbreviated Profile of Hearing Aid Benefit 
(APHAB).  Method: Twenty-three EAS users, implanted with 
either the PULSARCI 100 FLEX EAS provided with the DUET EAS 
processor or the COMBI40+ Medium provided with the TEM-
PO+ speech processor, were included. Electric stimulation 
was activated about 1 month postoperatively; ipsilateral 
acoustic stimulation was added 2 months thereafter. EAS 
 Received: March 1, 2011 
 Accepted: August 3, 2011 
 Published online: October 11, 2011 
 Prof. Wolfgang Gstoettner, MD 
 Medical University of Vienna 
 Department of Otolaryngology, Head and Neck Surgery 
 Waehringer Guertel 18–20, AT–1090 Vienna (Austria) 
 Tel. +43 140 400 3305, E-Mail wolfgang.gstoettner   @   meduniwien.ac.at 
 © 2011 S. Karger AG, Basel
0301–1569/11/0736–0321$38.00/0 
 Accessible online at:
www.karger.com/orl 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 2
:2
4:
30
 P
M
 Gstoettner et al. ORL 2011;73:321–329 322
from traditional instrument amplification. EAS was first 
performed in 1999  [1] and is now a routinely used treat-
ment method. The main focus of EAS is based on the use 
of residual acoustic hearing in the low frequencies. It is 
thus of crucial importance during EAS surgery to prevent 
any damage to the apical low-frequency regions of the 
cochlea by means of, for example, a limited insertion 
depth, shorter electrodes or flexible electrodes specifical-
ly designed for hearing preservation  [1–3] .
 When residual hearing is successfully preserved dur-
ing cochlear implantation, audiological outcome mea-
sures demonstrate that EAS users have a marked benefit 
and that a strong synergistic effect of using both electric 
and acoustic devices exists, which is particularly notice-
able in speech understanding in noise  [2, 4–7] as well as 
in music perception  [8] .
 In addition to these audiological outcome measures 
obtained by objective testing, subjective benefits are also 
of great importance. And, although the subjectively per-
ceived benefit generally corresponds with and supports 
the objectively measured improved speech perception, 
benefits seen in speech perception testing may not ac-
count for every aspect of subjective benefits. Studies (as 
reported in Cox et al.  [9] ) have shown that subjectively 
rated improvement in speech understanding, attributed 
to the hearing aid, accounts for less than 40% of the vari-
ance in satisfaction regarding the hearing aid. This result 
suggests that user satisfaction is in fact also greatly im-
pacted by other issues such as acoustic feedback, dexter-
ity or user expectations.
 To evaluate subjective benefits, patient self-report sur-
veys  [10] or questionnaires such as the Glasgow hearing 
aid benefit profile  [11] or the Abbreviated Profile of Hear-
ing Aid Benefit (APHAB)  [12, 13] are generally used. The 
APHAB questionnaire, as used in the present study, was 
designed for hearing-impaired patients to report the 
amount of trouble they are having with communication 
and noise in everyday situations. In the past, multiple 
studies have already been using the APHAB to obtain 
such subjective results  [14, 15] . However, since EAS is still 
a relatively new treatment method, only few studies have 
been done so far using the APHAB to investigate the sub-
jective benefits of EAS. Helbig et al.  [16] performed such 
a study, using the APHAB questionnaire, amongst speech 
perception tests, to evaluate the subjective benefit of a co-
chlear implant (CI)/EAS user upgrade to a combination 
of hearing aid and speech processor in one single device 
(DUET TM ). Before the upgrade, 6 of the 9 study subjects 
were CI-only users and did not use EAS as they consid-
ered it too cumbersome to wear 2 different devices (speech 
processor and in-the-ear hearing aid) in the same ear. 
After the upgrade, all subjects did not only perform 
equally well or better in the objective speech perception 
tests, but showed also a tendency towards fewer problems 
with the DUET EAS system in the subjective APHAB 
questionnaire. Furthermore, all subjects remained EAS 
users with the DUET system. This suggests that the sub-
jective benefit cannot only be attributed to the improved 
speech perception, but was also greatly influenced by the 
convenient fact that the EAS users were no longer re-
quired to wear 2 devices in the same ear but only one 
single device.
 The present study focuses even more specifically on 
the subject benefits of EAS and assesses the subjective 
benefits reported by EAS users over time using the 
APHAB.
 Subjects and Methods 
 Subjects 
 Twenty-three subjects with bilateral, symmetric hearing loss 
were enrolled in this investigation. Subjects were initially partici-
pants of 2 clinical trials which investigated the outcomes of EAS 
 [7, 17] . The inclusion criteria were the same in both studies ( ta-
ble 1 ), and each study site followed the same surgical protocol for 
atraumatic electrode insertion and the same recommended in-
sertion depth of 18–22 mm. In both studies two different elec-
trodes, however, both specifically designed for EAS treatment by 
MED-EL (Innsbruck, Austria) were used, namely the M-Elec-
trode and the FLEX EAS electrode. Both electrodes feature 12 stim-
ulation channels with contact spacing of 1.9 mm resulting in a 
total contact extent of 20.9 mm.
 Subjects from the FLEX EAS study were fit with the DUET EAS 
system which was the first device on the market that provided 
electric stimulation via the CI and acoustic amplification of au-
dible low-frequency sounds in one combined speech processor. 
Subjects from the M-Electrode study were fit with the TEMPO+ 
Table 1.  Inclusion criteria of M-Electrode and FLEXEAS study sub-
jects
Postlingual, nonprogressive sensorineural hearing loss
Monosyllable scores in quiet of ≤45% (M-Electrode study) or 
≤50% (FLEXEAS study) at 65 dB SPL in best-aided condition 
(Oticon Adapto P behind-the-ear hearing aid)
Pure-tone hearing levels:
125, 250 and 500 Hz: ≤65 dB HL
1,000 Hz: ≥60 dB HL (M-Electrode study) or ≥50 dB HL 
(FLEXEAS study)
2,000–8,000 Hz: ≥70 dB HL
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speech processor and a separate in-the-ear hearing aid (Oticon 
Adapto-P, Oticon, Denmark) which was added to the same ear (as 
no DUET EAS system was available at the time of this study).
 Eighteen subjects from the FLEX EAS study and, additionally, 5 
subjects from the M-Electrode study completed the APHAB ques-
tionnaire and were included in this analysis. 
 Methods 
 Preoperative Assessment 
 Before implantation, all subjects used their preferred, every-
day hearing condition. This means that some used hearing aids 
in both ears, some used a hearing aid in one ear and no acoustic 
amplification in the other ear, and some used no acoustic ampli-
fication at all in either ear. Thus, when answering the APHAB 
questions preoperatively, the subjects’ hearing conditions were 
those used in everyday life.
 CI and Hearing Aid (EAS) Fitting 
 The subjects were initially fitted with their speech processor 
(TEMPO+ or DUET) 3–5 weeks after cochlear implantation. The 
processor was fitted for the full frequency range available to pro-
vide adequate experience with electric stimulation via the CI 
alone. After 2 months, the acoustic amplification was added to the 
same ear, and thus the EAS mode was introduced to all subjects. 
The CI was fitted by determining at which frequency the audio-
gram surpassed 65 dB HL hearing loss. The low-frequency cutoff 
point of the electrical stimulation was set at this frequency point. 
The upper limit was set at 7,000 Hz. In both studies the acoustic 
stimulation was fitted in order to only amplify the audible low 
frequencies up to the frequency point where the audiogram 
reached 80 dB HL. For the M-Electrode group using a conven-
tional hearing aid, fitting was performed using the Oticon Genie 
fitting software.
 Postoperative Assessments 
 As described above, each subject completed 2 months of CI-
alone experience before the EAS mode was introduced. Thereaf-
ter, subjects had to complete the APHAB at EAS fitting as well as 
3, 6 and 12 months after EAS fitting. In all postoperative test in-
tervals when answering the APHAB questions, subjects referred 
to their hearing condition using EAS in the implanted ear and the 
hearing condition as used in everyday life in the contralateral ear, 
i.e. using a hearing aid or no acoustic amplification.
 Detailed information about the objective speech perception 
tests performed in the two clinical trials combined in this study 
can be found in the papers published by Helbig et al.  [17] and 
Gstoettner et al.  [7] .
 Abbreviated Profile of Hearing Aid Benefit 
 In the APHAB  [12, 13] , subjects report about the amount of 
trouble they are having with communication and noise in every-
day situations, i.e. the APHAB measures the percentage of diffi-
culty experienced by subjects. The APHAB comprises 24 items 
that are divided into 4 subscales and summarizes these in a glob-
al scale. ‘Ease of communication (EC)’ is defined as the strain of 
communicating under relatively favorable conditions. ‘Reverber-
ation (RV)’ considers communication in reverberant rooms such 
as classrooms, whilst ‘background noise (BN)’ considers commu-
nication in settings with high background noise levels. ‘Aversive-
ness (AV)’ evaluates the unpleasantness of environmental sounds. 
Each item of the APHAB is a statement, and the subject must 
choose whether this statement is true by choosing from 7 options, 
ranging from ‘A = always (99%)’ to ‘G = never (1%)’. Several of the 
statements are presented in reverse order so that subjects focus on 
the content of the questions. A detailed description on the admin-
istration and application is available in the paper of Cox  [13] .
 Statistical Analyses 
 Descriptive statistics were used to report baseline characteris-
tics (e.g. age and gender). Quantitative data are presented as mean 
and range (minimum and maximum), and qualitative data as ab-
solute and relative frequencies. The data distribution of the 
APHAB global scale and the 4 APHAB subscales (EC, RV, BN and 
AV) are shown in graphs (box plots). A value of 100% reflects the 
highest possible impairment, i.e. the higher the percentage, the 
more subjectively reported problems. The subjective benefit of 
EAS was measured using the APHAB at different test intervals af-
ter implantation and compared to the preoperative acoustic hear-
ing aid condition. One-way repeated-measures ANOVAs (GLM) 
with time as factor were performed on the APHAB global score 
and the APHAB subscales (EC, RV, BN and AV) to investigate if 
significant improvement over time occurred. For each ANOVA, 
Mauchly’s test of sphericity was applied. If sphericity could not be 
assumed, the Greenhouse-Geisser correction was used as part of 
the ANOVA. The Kolmogorov-Smirnov test was used to check the 
data distribution. To detect differences between the test intervals 
(difference from the preoperative testing to the first fitting, first 
fitting to the 3-month test interval, from the 3-month to the 
6-month test interval, and from the 6-month to the 12-month test 
interval) parametric paired-sample t tests were applied. 
 To determine the clinical relevance of EAS, a benefit score of 
the APHAB was assessed, according to the method of Cox and 
Alexander  [12] . The benefit score was calculated by subtracting 
the aided average (e.g. first fitting) from the unaided average (e.g. 
preoperative testing). If the difference in benefit scores on the 3 
subscales EC, RV and BN were at least 10% (difference in mean) 
greater for the respective test strategy, it can be concluded from 
the clinical perspective that this difference reflects a true benefit 
with a 95% probability.
 Statistical significance was set to p  ! 0.05. When considering 
Bonferroni’s adjustment for multiple comparisons, p values less 
than 0.0125 indicate statistical significance for 4 pairwise tests. 
SPSS 16.0 for Windows software (Chicago, Ill., USA) was used for 
all analyses. Graphs were created in Microsoft Office Excel 2003. 
 Ethics 
 This study was conducted according to EN 540 standards (the 
standards in operation at the time of the M-Electrode study) and 
ISO 14155 parts 1 and 2 for the FLEX EAS study. Ethics approval 
for the study was received from each participating institution, and 
all relevant competent authorities approved the study.
 Results 
 Data of 23 EAS users implanted with either the FLEX EAS 
or the M-Electrode were analyzed in this study. Twelve 
women (67%) and 6 men (28%) were included from the 
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FLEX EAS electrode study  [17] . The mean age at surgery 
was 51 years, with a range of 22–75 years. Nine patients 
(50%) were implanted in the left ear and 9 patients (50%) 
in the right. The mean age at onset of profound hearing 
loss for both ears was 44 years, with a range of 12–66 
years. The mean duration of deafness at assessment time 
was 20 years (range: 5–38 years). One woman (20%) and 
4 men (80%) were included from the M-Electrode study 
 [7] . The mean age at the time of surgery was 57 years, 
ranging from 48 to 69 years. Four subjects were implant-
ed in the left ear and 1 in the right. The mean age at onset 
of profound hearing loss was 43 years (range: 25–61 
years), and the mean duration of deafness was 24 years 
(range: 11–54 years).
 In  figures 1–5 , mean APHAB percentage scores for the 
global score and for the EC, RV, BN and AV subscales are 
shown for the different test intervals. The measured mean 
percentage of problems decreased from 74% before im-
plantation to 45% after 3 months of EAS use for the glob-
al scale, from 57 to 28% for the EC subscale, from 83 to 
55% for the RV subscale, from 82 to 53% for the BN sub-
scale and from 45 to 27% for the AV subscale.
 According to the results of one-way repeated-mea-
sures ANOVAs, the improvement over time with the EAS 
condition compared to the preoperative acoustic hearing 
aid condition for the global score and for all subscales was 
statistically highly significant [p  ! 0.001; global score: 
F(2.5, 46.9) = 26.91; EC: F(2.3, 42.9) = 15.20; RV: F(2.7, 
50.6) = 16.48; BN: F(2.6, 49.4) = 22.01; AV: F(1.9, 35.8) = 
3.35;  table 2 ].
 Statistical analyses investigating the differences be-
tween the single test intervals revealed significant im-
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 Fig. 1. APHAB global score: subjectively 
reported problems (black squares: mean; 
horizontal stripes: median) for patients us-
ing EAS over time. A value of 100% reflects 
the highest possible impairment. 
 Fig. 2. APHAB EC subscale: subjectively 
reported problems (black squares: mean; 
horizontal stripes: median) for patients us-
ing EAS over time. A value of 100% reflects 
the highest possible impairment. 
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 Fig. 3. APHAB RV subscale: subjectively 
reported problems (black squares: mean; 
horizontal stripes: median) for patients us-
ing EAS over time. A value of 100% reflects 
the highest possible impairment. 
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 Fig. 4. APHAB BN subscale: subjectively 
reported problems (black squares: mean; 
horizontal stripes: median) for patients us-
ing EAS over time. A value of 100% reflects 
the highest possible impairment. 
 Fig. 5. APHAB AV subscale: subjectively 
reported problems (black squares: mean; 
horizontal stripes: median) for patients us-
ing EAS over time. A value of 100% reflects 
the highest possible impairment. 
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provement for the global score and almost all subscales 
between the preoperative testing and the first fitting, and 
between the first fitting and the 3-month testing. The im-
provement for the AV subscale between the preoperative 
testing and the first fitting, and for the BN subscale be-
tween first fitting and 3-month testing was not signifi-
cant. Also, between the 3-month and 6-month testing and 
between the 6-month and 12-month testing, the differ-
ence was not statistically significant for the global score 
and the subscales, except for the EC subscale ( table 2 ).
 Using the method of Cox and Alexander  [12] to evalu-
ate the clinical relevance of the device, the mean differ-
ences in benefit scores on the 3 subscales EC, RV and BN 
between preoperative and first fitting results were higher 
than 10% (22, 20 and 24%, respectively) and thus reflect-
ed with 95% probability a true benefit of EAS. The AV 
subscale and comparisons between the preoperative and 
the 6-month as well as the 12-month interval showed a 
tendency to improved benefit but the results were not sig-
nificant from a clinical perspective according to the 
method of Cox and Alexander  [12] .
 Discussion 
 The present study used the APHAB questionnaire to 
assess the subjective benefits of EAS over the first 12 
months after EAS fitting. Although this field of applica-
tion was initially not intended for the APHAB as it was 
validated only for use in individuals using hearing aids 
 [12] , multiple studies in the past have already demonstrat-
ed the applicability of the APHAB questionnaire for in-
vestigating the subjective benefits of CIs  [14, 18] and EAS 
 [16, 17, 19] . Against this backdrop, we considered the 
APHAB to be a valid testing method for evaluating the 
subjective benefits of EAS.
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 Fig. 6. Preoperative results (= hearing aid 
condition), first fitting and 12-month test-
ing results of Hochmair-Schulz-Moser 
sentences in noise depicted separately for 
the whole sample (all: n = 23), the FLEX EAS 
sample (n = 18) and the M-Electrode sam-
ple (n = 5). Speech was presented at a level 
of 65 dB (FLEX EAS [17]) and 70 dB (M-
Electrode [7]). The signal-to-noise ratio 
was set at 10 dB. Horizontal lines of the box 
plot represent median values, black squares 
mean values. 
Table 2.  Results of paired-sample t tests to detect mean differ-
ences between the single test intervals for the APHAB global score 
and the EC, RV, BN and AV subscales
Preop. vs. 
EAS fit
EAS fit vs. 
3 months
3 vs. 6 
months
6 vs. 12 
months
Global
Difference 23.4 7.9 –0.6 –1.5
p value (2-tailed) <0.001 0.001 0.768 0.405
EC
Difference 23.7 8.6 1.0 –5.2
p value (2-tailed) 0.001 0.014 0.700 0.018
RV
Difference 21.7 9.1 –2.1 2.1
p value (2-tailed) <0.001 0.001 0.409 0.487
BN
Difference 24.7 6.0 –0.6 –1.3
p value (2-tailed) <0.001 0.042 0.790 0.513
AV
Difference 7.2 9.4 –2.5 0.6
p value (2-tailed) 0.192 0.015 0.413 0.826
S ignificant results of p < 0.0125 are in italics.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 2
:2
4:
30
 P
M
 Subjective Benefit of EAS with the 
APHAB Questionnaire 
ORL 2011;73:321–329 327
 The results of the APHAB show that subjects per-
ceived an immediate benefit with EAS with statistically 
significant differences between the acoustic-only ampli-
fication pre-operatively and the EAS at the first fitting as 
well as between the first fitting and the 3-month interval 
in the global scale and almost all subscales. After this sta-
tistically significant decrease in impairment, the scores 
stabilized following the 3-month interval at this low level 
of impairment ( fig. 1–5 ). These results correspond with 
the objective speech perception results ( fig. 6 ) [for more 
detailed speech perception results and test conditions, see 
also  7, 17 ].  Figure 6 shows the improvement in speech per-
ception over time in the Hochmair-Schulz-Moser sen-
tence test in noise. We decided to use the Hochmair-
Schulz-Moser sentence test for a direct comparison here 
as it is the test closest to a ‘real-life’ situation and is thus 
best to be compared with the APHAB, in which the im-
paired patients report their amount of trouble with com-
munication and noise in everyday situations. The im-
provement was statistically significant for the combined 
groups [repeated-measure ANOVAs: F(2, 38) = 11.81; p  ! 
0.001] and for the FLEX EAS group [F(2, 30) = 12.07; p  ! 
0.001] but not for the M-Electrode group [F(2, 6) = 2.85; 
p = 0.237]. Furthermore, the difference was statistically 
significant between the preoperative and the first fitting 
interval (p = 0.008) and between the first fitting and the 
12-month interval (p = 0.021). Thus, the APHAB results 
as well as the speech perception results correlate very well 
and demonstrate an immediate benefit of EAS, suggest-
ing that the APHAB is a suitable method of measuring 
subjective benefits of EAS. However, in contrast to the 
objective speech perception results, which improved over 
a longer period of time (Hamzavi et al.  [20] : up to 72 
months; Tyler et al.  [21] : up to 18–30 months), suggesting 
that more time to get accustomed to a device and/or a new 
coding strategy further increases speech perception, the 
APHAB results in our study stabilized after the 3-month 
interval, which might be attributed to fulfilled expecta-
tions.
 It is furthermore interesting to note that this immedi-
ate benefit, especially the benefit between the preopera-
tive and first fitting interval, could be observed consider-
ing that all subjects experienced a drop in the threshold 
levels after surgery at the critical frequencies of 125, 250 
and 500 Hz ( fig. 7 ). Subjects had a mean hearing loss of 
12 dB (SD = 11) at 125 Hz, of 14 dB (SD = 12) at 250 Hz 
and of 22 dB (SD = 17) at 500 Hz between preoperative 
testing and first fitting. After this initial drop, the resid-
ual hearing was stable over time and therefore should not 
have had a further influence on the results presented here 
( fig. 7 ). Our results suggest that EAS users have relevant 
subjective and objective benefit from the treatment even 
if some hearing is lost postoperatively. 
 Similar APHAB results, showing an immediate ben-
efit, are also reported in an EAS study by Skarzynski et 
al.  [5] . In the APHAB global scores, subjects showed sta-
tistically significant differences between the preoperative 
and the 6-month intervals (p = 0.085) as well as between 
the preoperative and the 12-month intervals (p = 0.087), 
but not between the 6- and the 12-month intervals. Ac-
cording to Skarzynski et al., the level of (direct) benefit 
reported by subjects may also reflect if the fitting param-
eters correspond with the individual’s needs or if chang-
es in fitting have to be made. In their study, the results in 
the AV subscales worsened within the first months after 
implantation. Skarzynski et al. related this increased im-
pairment to the fact that the subjects were not accus-
tomed to the sound and that the fitting parameters put 
too much emphasis on the high frequencies. In our study, 
an improvement in the AV condition was still observable, 
although it was not statistically significant for the major-
ity of test intervals. Nevertheless, the explanation by 
Skarzynski et al.  [5] for the worsened results in their AV 
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